ERBB2 and breast cancer: After the FDA approval of trastuzumab for the treatment of metastatic BC patients with HER2 overexpression and/or gene amplification, an emerging body of preclinical and clinical data has started to come up, highlighting the effectiveness of immunotherapies in BC.